Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Sandra M E GeurtsKhava I E IbragimovaNan DingMarissa MeegdesFrans ErdkampJoan B HeijnsJolien TolBirgit E P J VriensMarcus W DercksenKirsten N A AalderingManon J A E PepelsLinda van de WinkelNatascha A J B PetersAgnes J van de WouwSabrina A J G MaaskantNathalie J A Teeuwen-DedroogThiemo J A van NijnattenMaaike de BoerVivianne C G Tjan-HeijnenPublished in: Breast cancer research and treatment (2024)
The prognosis of patients with de novo HER2 + ABC has improved considerably. Since 2013 one in four patients were alive and free from progression on first-given therapy for at least five years.